HeartSciences Inc. (HSCS) EBITDA Margin (2021 - 2025)

HeartSciences (HSCS) has reported EBITDA Margin for 5 consecutive years, with 85713.23% the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, EBITDA Margin changed N/A year-over-year to 85713.23%; the trailing twelve-month figure through Apr 2026 stood at 96946.89% (down 5310137.0% YoY), and the FY2026 full-year result was 194787.38%, down 277425.0% from the prior year.
• EBITDA Margin advanced to 85713.23% in Q4 2025 per HSCS's latest filing, from 98637.84% in the prior quarter.
• Across five years, EBITDA Margin topped out at 9011.84% in Q3 2021 and bottomed at 98637.84% in Q3 2025.
• Historically, EBITDA Margin has averaged 48780.2% across 5 years, with a median of 44418.82% in 2025.
• The sharpest annual moves came in 2022 and 2024: EBITDA Margin plunged 3567869 bps in 2022, then soared 5676700 bps in 2024.
• Over 5 years, EBITDA Margin stood at 9011.84% in 2021, then tumbled by 396 bps to 44690.53% in 2022, then gained by 10 bps to 40254.95% in 2023, then surged by 74 bps to 10376.75% in 2024, then plunged by 726 bps to 85713.23% in 2025.
• According to Business Quant data, EBITDA Margin over the past three periods registered 85713.23%, 98637.84%, and 44147.1% for Q4 2025, Q3 2025, and Q2 2025 respectively.